Comparison of reduced-intensity SCT conditioning regimens in poor risk AML

For many patients with hematological malignancies, like acute myeloid leukemia (AML), with poor outcome prognosis, allogeneic stem cell transplantation (allo-SCT) at first remission (CR1) is a common treatment strategy.¹ However, allo-SCT is associated with significant non-relapse mortality (NRM) when combined with traditional myeloablative conditioning regimens. Conventional myeloablation is based on high intensity busulfan (Bu) or total body irradiation (TBI) in combination with cyclophosphamide (Cy).^1,2 To reduce the risk of toxicity, reduced-intensity or non-myeloablative conditioning regimens have been developed. Nevertheless, these are not as efficient in reducing disease recurrence. To find the right balance between efficacy and safety, reduced toxicity regimens using Bu or TBI at moderate doses together with fludarabine (Flu) have been proposed.^1,2

During the 61^st American Society of Hematology Annual Meeting & Exposition on Monday 9^th December 2019, Sebastian Giebel from Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, PL, presented the results of a retrospective study by the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) that compared reduced toxicity Bu/Flu to similar intensity TBI/Flu in patients with AML who were treated with allo-SCT. The primary endpoint of this study was leukemia-free survival (LFS), while the key secondary objectives included, NRM, relapse incidence (RI), overall survival (OS), and graft-versus-host disease (GvHD)-free relapse-free survival (GRFS).

Read more on the use of transplantation for the treatment of AML here.

Study design² 

• Retrospective analysis from data obtained by the EBMT registry (2006-2018)
• Adult patients > 18 years with intermediate or poor-risk AML, who had received matched sibling donor or unrelated donor allo-SCT and are in CR1
• Dosing of reduced-intensity conditioning regimens:
  • Bu/Flu (N= 350): intravenous Bu at a total dose 9.6mg/kg for three days plus Flu
  • TBI/Flu (N= 168): TBI at a total dose of 8Gy plus Flu
• Patient and transplantation characteristics are shown in Table 1

Key findings² 

• Engraftment rate was 99% for both regimens
• In the total patient cohort, univariate analysis revealed that:
  • RI was significantly higher in the Bu/Flu group than those receiving TBI/Flu (p= 0.01)
  • NRM (p= 0.18) and LFS (p= 0.15) were not significantly different between the two conditioning regimens
  • Acute GvHD (aGvHD) of grade 3-4 was the only significant GvHD-related difference between the two conditioning regimens. This was observed when stratifying patients by age. In patients < 50 years old grade 3-4 aGvHD was significantly lower with TBI/Flu than Bu/Flu (Table 2)

• When comparing patients < 50 years of age with those ≥ 50 years, Cox modelling revealed that (Table 3):
  • In patients < 50 years of age, RI, LFS, OS, GRFS and incidence of aGvHD grade 3-4 were significantly improved with TBI/Flu compared to Bu/Flu
  • In patients ≥ 50 years only NRM was significantly higher with TBI/Flu vs Bu/Flu

Conclusion

Both the reduced-intensity conditioning regimens examined in this retrospective study (TBI/Flu and Bu/Flu) resulted in low RI rates and low NRM following allo-SCT. Thus, they both present a good regimen for patients with AML in CR1. When looking at the patient population in two different age groups (< 50 or ≥ 50 years old), TBI/Flu was more efficacious than Bu/Flu in younger patients with a lower RI and higher GFRS, LFS, and OS. The incidence of acute grade 3-4 GvHD was also significantly reduced with TBI/Flu vs Bu/Flu in younger patients. Nevertheless, in older patients (≥ 50 years old) TBI/Flu was associated with an increased NRM risk and should be used with caution. Despite the limitation of the retrospective design of this study, the results are very informative and encourage further prospective clinical trials with age-dependent stratification of patients to such conditioning regimens.